Evaluating the effect of rapamycin treatment in Alzheimer ’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol

Rapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, and preclinical data demonstrate that it is a promising candidate for a general gero- and neuroprotective treatment in hu...

Source: BMC Neurology - April 4, 2024 Category: Neurology Authors: Jonas E. Svensson, Martin Bolin, Daniel Thor, Pete A. Williams, Rune Brautaset, Marcus Carlsson, Peder S örensson, David Marlevi, Rubens Spin-Neto, Monika Probst, Göran Hagman, Anton Forsberg Morén, Miia Kivipelto and Pontus Plavén-Sigray Tags: Study Protocol Source Type: research